MENU
+Compare
ADIL
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$0.21
Change
-$0.21 (-50.00%)
Capitalization
5.87M

ADIL Adial Pharmaceuticals Forecast, Technical & Fundamental Analysis

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company... Show more

ADIL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ADIL with price predictions
Feb 02, 2026

Momentum Indicator for ADIL turns negative, indicating new downward trend

ADIL saw its Momentum Indicator move below the 0 level on January 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 110 similar instances where the indicator turned negative. In of the 110 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADIL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ADIL entered a downward trend on January 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADIL's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for ADIL just turned positive on January 05, 2026. Looking at past instances where ADIL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADIL advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.303) is normal, around the industry mean (27.778). P/E Ratio (0.000) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.006).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADIL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ADIL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of medications to treat addiction and related disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
4870 Sadler Road
Phone
+1 804 487-8196
Employees
7
Web
https://www.adialpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLSK11.360.32
+2.90%
CleanSpark
CNEY1.030.02
+1.98%
CN Energy Group Inc
OMEX1.900.01
+0.53%
Odyssey Marine Exploration
WRLD120.96-2.24
-1.82%
World Acceptance Corp
FN448.53-51.08
-10.22%
Fabrinet

ADIL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADIL has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ADIL jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADIL
1D Price
Change %
ADIL100%
+0.80%
SYRE - ADIL
39%
Loosely correlated
+2.41%
VANI - ADIL
37%
Loosely correlated
+5.76%
VTVT - ADIL
29%
Poorly correlated
+8.19%
BPMUF - ADIL
28%
Poorly correlated
N/A
GDTC - ADIL
27%
Poorly correlated
+6.62%
More